SEMA3A and acute kidney injury: Given the prevalence of AKI associated with OLT and its associated morbidity and mortality, therapeutic studies based on the diagnosis of AKI using a panel of biomarkers including netrin-1, sema3A, IGFBP-1 and TIMP-2 [28] may be possible in the future.